NASDAQ: DXCMDexcom Inc Stock
$138.01+0.14 (+0.1%)
Updated Apr 25, 2024
DexCom shares are trading lower.... find out Why DXCM Price Moved with a free WallStreetZen account
Why Price MovedDXCM Price
$138.01
Fair Value Price
$29.56
Market Cap
$54.88B
52 Week Low
$74.75
52 Week High
$142.00
P/E
83.64x
P/B
24.43x
P/S
14.24x
PEG
15.59x
Dividend Yield
N/A
Revenue
$3.80B
Earnings
$639.30M
Gross Margin
62.8%
Operating Margin
20.89%
Profit Margin
16.8%
Debt to Equity
1.89
Operating Cash Flow
$802M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DXCM Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DXCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DXCM ($138.01) is overvalued by 366.82% relative to our estimate of its Fair Value price of $29.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DXCM ($138.01) is not significantly undervalued (366.82%) relative to our estimate of its Fair Value price of $29.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DXCM ($138.01) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DXCM due diligence checks available for Premium users.
Be the first to know about important DXCM news, forecast changes, insider trades & much more!
DXCM News
Valuation
DXCM fair value
Fair Value of DXCM stock based on Discounted Cash Flow (DCF)
Price
$138.01
Fair Value
$29.56
Overvalued by
366.82%
DXCM ($138.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DXCM ($138.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DXCM ($138.01) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DXCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
83.64x
Industry
29.73x
Market
40.97x
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DXCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
24.43x
Industry
3.71x
DXCM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DXCM price to earnings growth (PEG)
For valuing profitable companies with growth potential
DXCM is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DXCM's financial health
Profit margin
Revenue
$921.0M
Net Income
$146.4M
Profit Margin
15.9%
DXCM's Earnings (EBIT) of $794.10M... subscribe to Premium to read more.
Interest Coverage Financials
DXCM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.5B
Liabilities
$4.2B
Debt to equity
1.89
DXCM's short-term assets ($4.62B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DXCM's short-term assets ($4.62B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DXCM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DXCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$209.2M
Investing
$74.8M
Financing
$4.7M
DXCM's operating cash flow ($802.30M)... subscribe to Premium to read more.
Debt Coverage Financials
DXCM vs Medical Device Stocks
Dexcom Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.